Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2004

01-12-2004 | Original Article

Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer

Authors: Minoru Fukuda, Mikio Oka, Hiroshi Soda, Akitoshi Kinoshita, Masaaki Fukuda, Seiji Nagashima, Mutsuo Kuba, Hiroshi Takatani, Junji Tsurutani, Yoichi Nakamura, Takashi Kasai, Yuichi Inoue, Yoshifumi Soejima, Shigeru Kohno, The Nagasaki Thoracic Oncology Group

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2004

Login to get access

Abstract

Purpose

Irinotecan, a topoisomerase I inhibitor, is an effective agent for non-small-cell lung cancer (NSCLC). To determine the efficacy and toxicity of irinotecan and carboplatin, we conducted a phase II study in 61 patients with advanced NSCLC.

Methods

Every 4 weeks, the patients received irinotecan 50 mg/m2 (days 1, 8 and 15) and carboplatin (day 1) with a target AUC of 5 mg min/ml using the Chatelut formula.

Results

All patients were evaluable for toxicity, and of 59 patients evaluable for response, 20 achieved a partial response and 26 showed no change. The overall response rate was 34% (95% confidence interval 23–48%). Grade 3 or 4 anemia, leukopenia, neutropenia, thrombocytopenia and diarrhea occurred in 32%, 32%, 60%, 25%, and 7%, respectively. The median survival time and 1-year, and 2-year survival rates were 10.0 months, 37.6%, and 15.2%, respectively.

Conclusions

Irinotecan with carboplatin is effective for advanced NSCLC and safe.
Literature
1.
Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722PubMed
2.
Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD (1989) Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715PubMed
3.
Masuda N, Kudoh S, Fukuoka M (1996) Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol Hematol 24:3CrossRefPubMed
4.
Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M, Saijo N (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in a human small cell lung cancer cells. Cancer Res 56:789PubMed
5.
Kano Y, Akutsu M, Suzuki K, Yoshida M (1993) Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk Res 17:113CrossRefPubMed
6.
Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50:5919PubMed
7.
Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, Negoro S, Nishikawa H, Katakami N, Nakagawa K, Niitani H (1998) Phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. Br J Cancer 78:251PubMed
8.
Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M, CPT-11 Lung Cancer Study Group West (2003) Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88:335CrossRefPubMed
9.
Niho S, Nagao K, Nishiwaki Y, Yokoyama A, Saijo N, Ohashi Y, Niitani H, The Irinotecan Lung Cancer Study Group (1999) Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:492a
10.
De Vore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, Eckhardt SG, Elfring GL, Schaaf LJ, Hanover CK, Miller LL (1999) Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 17:2710PubMed
11.
Rose WC, Schurig JE (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12:1CrossRef
12.
Lokich J, Anderson N (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 9:13CrossRefPubMed
13.
Bunn PA Jr (2002) Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20:23SPubMed
14.
Fukuda M, Oka M, Soda H, Terashi K, Kawabata S, Nakatomi K, Takatani H, Tsurutani J, Tsukamoto K, Noguchi Y, Fukuda M, Kinoshita A, Kohno S (1999) Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 5:3936
15.
Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748PubMed
16.
Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing schema for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylato-platinum. Cancer Res 45:6502PubMed
17.
Duffull SB, Robinso BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33:161PubMed
18.
Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573PubMed
19.
Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718PubMed
20.
WHO (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva
21.
Simon R (1987) How large should be a phase II trial of a new drug? Cancer Treat Rep 71:1079PubMed
22.
Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457
23.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92CrossRefPubMed
24.
Takeda K, Negoro S, Ohashi Y, Saijo N, Nishiwaki Y, Tamura T, Nakagawa K, Kubota K, Ariyoshi Y, Fukuoka M (2003) Preliminary results of four arm cooperative study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan. Lung Cancer 41:S64CrossRef
25.
Takeda K, Takefuji N, Uejima H, Yoshimura N, Terakawa K, Negoro S (2002) Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. Lung Cancer 38:303CrossRefPubMed
26.
Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210PubMed
Metadata
Title
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer
Authors
Minoru Fukuda
Mikio Oka
Hiroshi Soda
Akitoshi Kinoshita
Masaaki Fukuda
Seiji Nagashima
Mutsuo Kuba
Hiroshi Takatani
Junji Tsurutani
Yoichi Nakamura
Takashi Kasai
Yuichi Inoue
Yoshifumi Soejima
Shigeru Kohno
The Nagasaki Thoracic Oncology Group
Publication date
01-12-2004
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2004
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0805-2

Other articles of this Issue 6/2004

Cancer Chemotherapy and Pharmacology 6/2004 Go to the issue

Original Article

A 150-kDa glycoprotein isolated from Solanum nigrum L. has cytotoxic and apoptotic effects by inhibiting the effects of protein kinase C alpha, nuclear factor-kappa B and inducible nitric oxide in HCT-116 cells

Original Article

Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer

Original Article

Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract

Original Article

A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases

Original Article

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors

Original Article

Synergistic killing of human leukemia cells by antioxidants and trichostatin A
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits